Profile picture

Hadine Joffe, M.D.

Professor of Psychiatry, Beth Israel Deaconess Medical Center
Head of the Department of Psychiatry at Beth Israel Deaconess Medical Center, Beth Israel Deaconess Medical Center
Harvard Title

Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health 

Administrative and Hospital Titles

Chair and Psychiatrist-in Chief of the Department of Psychiatry at Beth Israel Deaconess Medical Center

Other Affiliations

Dana-Farber/Harvard Cancer Center Breast Cancer Program, Psychosocial Oncology and Palliative Care at Dana-Farber Cancer Institute 

Address

Beth Israel Deaconess Medical Center
Department of Psychiatry
330 Brookline Ave
Boston, MA 02215

Publications View
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
Authors: Newton KM, Carpenter JS, Guthrie KA, Anderson GL, Caan B, Cohen LS, Ensrud KE, Freeman EW, Joffe H, Sternfeld B, Reed SD, Sherman S, Sammel MD, Kroenke K, Larson JC, Lacroix AZ.
Menopause
View full abstract on Pubmed
The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
Authors: Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H.
J Clin Endocrinol Metab
View full abstract on Pubmed
A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.
Authors: Joffe H, Crawford S, Economou N, Kim S, Regan S, Hall JE, White D.
Sleep
View full abstract on Pubmed
Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol.
Authors: Joffe H, White DP, Crawford SL, McCurnin KE, Economou N, Connors S, Hall JE.
Menopause
View full abstract on Pubmed
Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.
Authors: Freeman MP, Hirschberg AM, Wang B, Petrillo LF, Connors S, Regan S, Joffe H, Cohen LS.
Maturitas
View full abstract on Pubmed
Disparate rates of new-onset depression during the menopausal transition in 2 community-based populations: real, or really wrong?
Authors: Harlow BL, MacLehose RF, Smolenski DJ, Soares CN, Otto MW, Joffe H, Cohen LS.
Am J Epidemiol
View full abstract on Pubmed
Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Authors: Joffe H, Guthrie KA, Larson J, Cohen LS, Carpenter JS, Lacroix AZ, Freeman EW.
Menopause
View full abstract on Pubmed
Antidepressant use after discontinuation of hormone therapy: what can one infer about post-hormone therapy depression?
Authors: Joffe H.
Menopause
View full abstract on Pubmed
Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
Authors: LaCroix AZ, Freeman EW, Larson J, Carpenter JS, Joffe H, Reed SD, Newton KM, Seguin RA, Sternfeld B, Cohen L, Ensrud KE.
Maturitas
View full abstract on Pubmed
Psychosocial features associated with lifetime comorbidity of major depression and anxiety disorders among a community sample of mid-life women: the SWAN mental health study.
Authors: Cyranowski JM, Schott LL, Kravitz HM, Brown C, Thurston RC, Joffe H, Matthews KA, Bromberger JT.
Depress Anxiety
View full abstract on Pubmed